The United States vaccines market size was valued at USD 29.5 billion in 2024 and is projected to hit around USD 60 billion by 2033, growing at a CAGR of 8.2% during the forecast period 2025 to 2033.
United States Vaccine Market Growth Drivers
One of the foremost factors influencing the expansion of the vaccine market in the United States is the rising prevalence of infectious diseases. With the emergence of new pathogens and variants, the demand for effective vaccines has surged. Additionally, advancements in biotechnology and genetic research are leading to the development of more effective and targeted vaccine formulations.
Another critical catalyst is the robust investment in vaccine research and development. Government agencies and private organizations alike are funneling funds into vaccine projects, accelerating the pace of innovation. Moreover, regulatory support and streamlined approval processes have encouraged manufacturers to bring new vaccines to market more quickly.
United States Vaccines Market Synopsis
This report presents an in-depth assessment of the United States vaccines market dynamics, opportunities, future road map, competitive landscape, and discusses major trends. The study provides the most recent industry data on the current state of the US vaccines market as well as its prospects. Forecasts from 2025 to 2033 are included in the report together with historical market data for 2023-2024. A comprehensive analysis has been done on market share with the percentage of all the 47 vaccines brand used in the United States.
The size of the US vaccines market in terms of value is thoroughly examined in the market report. The report offers a thorough understanding of the present and upcoming trends in the US vaccines market. Additionally, the study examines the market evaluation of the top 47 vaccines in the United States from 2023 to 2024, as well as forecasts through 2033. Along with the most recent data on the vaccine’s pricing analysis, insights, and trends, the report also covers the regulatory environment surrounding the US vaccines industry.
Additionally, the study monitors and evaluates competition trends, such as distribution, exclusive and license agreements, partnership agreements, collaboration, new vaccine innovations, and market research and development activities. The report also provides a thorough analysis of the variables that drive and impede market growth, as well as the changing trends in the industry.
The report also analyses detailed profiles of innovative and leading players with information on business overview, companies’ vaccines portfolio, promising vaccines in the clinical development, and the latest developments
Report Scope of the United States Vaccines Market
- The United States vaccines market size and forecast for the next eight year,2023 - 2033
- Comprehensive analysis of the top 47 vaccines market value in the United States with a 8-year forecast
- A complete examination of the market share and year-over-year growth rate of the top 47 vaccine brands
- Provides in-depth information on the most recent trends, insights, and pricing analysis
- Provides a thorough examination of the changing market trends, factors that are driving and limiting the US vaccines market.
- An insightful study of promising vaccines in clinical development has been conducted.
- Provides detailed information on the US vaccines market’s regulatory environment
- Tracks competitive developments, approaches, recent industry developments, partnership, collaboration deals, distribution, exclusive, and licensing agreement
- A thorough listing of the top companies, along by an analysis of their current vaccines portfolio, promising clinical development vaccines, and recent developments
Key Players in the United States Vaccines Market
- Pfizer
- Merck
- Grifols
- Sanofi Pasteur
- AstraZeneca
- GlaxoSmithKline (GSK)
- Bavarian Nordic
- Seqirus (CSL Limited)
- Dynavax Technologies Corporation
The Market Value and Eight-Year Forecast for the Top 47 Vaccines Brand
- Daptacel
- Quadracel
- Kinrix
- Vaxelis
- IPOL
- Vaqta
- Havrix
- Twinrix
- Engerix B
- Recombivax HB
- PedvaxHIB
- ActHIB
- Hiberix
- MenQuadfi
- Tenivac
- Penbraya
- Prevnar 20
- Gardasil 9
- Fluzone
- Vaxneuvance
- Fluad
- Varivax
- Abrysvo
- Proquad
- Pneumovax 23
- Fluarix
- FluLaval
- M-M-R II
- Adacel
- Boostrix
- Bexsero
- Menveo
- Trumenba
- Shingrix
- Pentacel
- Rotateq
- Rotarix
- Pediarix
- Infanrix
- Heplisav-B
- Capvaxive
- Arexvy
- FluMist TIV
- Flucelvax TIV
- Afluria TIV
- Jynneos
- Beyfortus
Key Questions the Report Addresses
- What is the state of the US vaccines market right now?
- How big is the US vaccines market overall, and what is the prediction (until 2033)?
- Which vaccines are the most popular? How much revenue can they make by 2033?
- Which vaccine provides the highest market share?
- What is the regulatory framework in the United States vaccines market?
- What are the major growth drivers of the United States vaccines market?
- What are the major inhibitors of the United States vaccines market?
- What are the major deals and agreement happenings in the United States vaccines market?
- What are the United States vaccines pricing trends and analysis?
- What are the various vaccines available in the United States?
- Who are the top market players? What are their happenings, current developments, and scenarios?
- How is the market predicted to develop in the future?
Table of Contents
1. Introduction2. Research Methodology3. Executive Summary
Samples
LOADING...
Companies Mentioned
- Pfizer
- Merck
- Grifols
- Sanofi Pasteur
- AstraZeneca
- GlaxoSmithKline (GSK)
- Bavarian Nordic
- Seqirus (CSL Limited)
- Dynavax Technologies Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 230 |
| Published | May 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 29.5 Billion |
| Forecasted Market Value ( USD | $ 60 Billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | United States |
| No. of Companies Mentioned | 9 |
